Ancora Heart, Inc articles

Ancora Heart Inc., a Santa Clara, Calif.-based company looking to help those with heart failure, is heralding results from an interim analysis of patients treated in a U.S. early feasibility study evaluating the safety of the investigational Accucinch ventricular repair system.

The multicenter, nonrandomized, prospective study is assessing the system in patients with symptomatic heart failure and concomitant functional mitral regurgitation (FMR) who have stable symptoms on guideline-d

Interim study results from systolic heart failure patients treated with percutaneous therapy designed to improve left ventricular function presented at TCT 2019

Santa Clara, Calif.–September 25, 2019–Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced results from an interim analysis of heart failure patients treated in the CorCinch FMR study, a U.S. early feasibility study evaluating the safety of the invest